drugset
drugset / Trial / NCT05693844

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

NCT05693844 ↗

Phase 1/2 Recruiting 15 enrolled Chinese PLA General Hospital UTC Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

In preclinical study, investigators have demonstrated that the newly developed pan-T booster (harbouring CD40 agonist and one T cell costimulator agonist) co-expressing MSLN CAR T cell possess more powerful antitumor activity than previously reported MSLN-CAR T cells. In this clinical trial, enrolled patients receive an initial dose of pan-T booster co-expressing MSLN CAR T cells at 1×10\^6 cells/kg based on the basic principle of dose escalation design, in order to evaluate the safety, feasibility, pharmacokinetics/pharmacodynamics, and efficacy of pan-T booster co-expressing MSLN CAR T cell in vivo.

Timeline

Start
2023-01-20
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pan-T booster co-expressing MSLN CAR T cell Cell therapy 1e+06 cells/kg —
Subject Pan-T booster co-expressing MSLN CAR T cell Cell therapy 3e+06 cells/kg —
Subject Pan-T booster co-expressing MSLN CAR T cell Cell therapy 6e+06 cells/kg —
Background Albumin-Bound Paclitaxel Unknown 100 mg/m2 Intravenous
Background Albumin-Bound Paclitaxel Unknown 200 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 15 mg/kg Intravenous
Background Cyclophosphamide Other / unclassified 30 mg/kg Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

No indication recorded.